TG Therapeutics, Inc. To Present At The 15th Annual BIO CEO & Investor Conference

NEW YORK, Feb. 8, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 15 th Annual BIO CEO & Investor Conference being held at the Waldorf Astoria Hotel in New York City. Mr. Weiss' presentation is scheduled to take place on Monday, February 11, 2013 at 3:30 PM EST. A live webcast of this presentation will be available on the Events page of the Company's website at www.tgtherapeutics.com .

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two advanced therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma and Chronic Lymphocytic Leukemia. TG Therapeutics is also developing TGR-1202, a highly specific, orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. TG Therapeutics is headquartered in New York City.

The TG Therapeutics logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11857

TGTX - G
CONTACT: Jenna Bosco         Director - Investor Relations         TG Therapeutics, Inc.         Telephone: 212.554.4484         Email: ir@tgtxinc.com

TG Therapeutics Logo

If you liked this article you might like

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Biotech M&A: Who's Next After Gilead-Kite?

Biotech M&A: Who's Next After Gilead-Kite?

Lockheed Martin, TG Therapeutics, HD Supply: 'Mad Money' Lightning Round

Lockheed Martin, TG Therapeutics, HD Supply: 'Mad Money' Lightning Round

Bitter Battle Between Growth and Value: Cramer's 'Mad Money' Recap (Wednesday 6/21/17)

Bitter Battle Between Growth and Value: Cramer's 'Mad Money' Recap (Wednesday 6/21/17)